NIH, Partners Announce $230M Accelerating Medicines Partnership
The National Institutes of Health (NIH) recently announced the Accelerating Medicines Partnership (AMP), a new $230 million public-private venture to transform the current model for developing new diagnostics and treatments by jointly identifying and validating promising biological targets of disease. The first phase of AMP will begin with pilot projects in three disease areas — Alzheimer’s disease, Type 2 diabetes and lupus. NIH and its partners will make the AMP data and analyses publicly accessible to the broad biomedical community.